Saroglitazar

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H29NO4S
Molecular Weight	439.567
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)C(O)=O

InChI

InChIKey=MRWFZSLZNUJVQW-DEOSSOPVSA-N

InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H29NO4S
Molecular Weight	439.567
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://timesofindia.indiatimes.com/business/india-business/Zydus-Group-launches-new-diabetic-drug/articleshow/20459662.cms | https://www.ncbi.nlm.nih.gov/pubmed/25674933 | https://clinicaltrials.gov/ct2/show/NCT03112681 | https://clinicaltrials.gov/ct2/show/NCT03863574

Saroglitazar, a dual peroxisome proliferator-activated receptor PPAR-α/γ agonist, was an emerging therapeutic option on glycemic and lipid parameters. The Zydus Group has launched LipaglynTM ((Saroglitazar) in India for diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In addition, saroglitazar participated in phase II clinical trials that completed enrolment in patients with primary biliary cholangitis and in patients with non-alcoholic steatohepatitis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26171220 \| https://www.drugdevelopment-technology.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/	Agonist 2752		0.65 pM [EC50]
Peroxisome proliferator-activated receptor gamma 118 Target ID: CHEMBL235 Sources: https://www.drugdevelopment-technology.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/ \| https://www.ncbi.nlm.nih.gov/pubmed/26171220	Agonist 2752		3.0 nM [EC50]

PubMed

Title	Date	PubMed
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.	2018-12	29224415
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.	2018-06	29164820
Saroglitazar for the treatment of dyslipidemia in diabetic patients.	2015-03	25674933

Patents

Sample Use Guides

In Vivo Use Guide

Primary Biliary Cirrhosis: saroglitazar magnesium 2 mg or 4 mg tablet Once daily for 16 weeks Non Alcoholic Steatohepatitis: Saroglitazar Magnesium 2 mg or 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:30:47 GMT 2025` Edited by `admin` on `Mon Mar 31 21:30:47 GMT 2025`
Record UNII	E0YMX3S4JD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Saroglitazar

Official Name

English

(2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid

Preferred Name

English

saroglitazar [INN]

Common Name

English

Benzenepropanoic acid, á-ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]-, (áS)-

Systematic Name

English

SAROGLITAZAR [USAN]

Common Name

English

Saroglitazar [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98233